NEW BRUNSWICK, N.J. — Johnson & Johnson and its Janssen Pharmaceutical Cos. will announce plans to launch or file for regulatory approval more than 10 new products with “blockbuster potential” between 2017 and 2021, as well as 50-plus line extensions of new medicines, senior executives said Wednesday during an industry analysts meeting.
Among the late-stage blockbusters projected to file for regulatory approvals between 2017 and 2021, include:
- apalutamide (ARN-509) for pre-metastatic prostate cancer;
- esketamine for treatment-resistant depression;
- talacotuzumab (CSL362) for acute myeloid leukemia;
- erdafitinib (FGFR Inhibitor) for solid tumors;
- niraparib for prostate cancer;
- imetelstat for myelofibrosis;
- pimodivir (JNJ-3872) for influenza A;
- lumicitabine (JNJ-1575) for respiratory syncytial virus (RSV) infection; and,
- JNJ-7922 (orexin-2 antagonist) for adjunctive treatment for major depressive disorder.
The company also said it will share its plans to continue driving sustainable growth by leveraging its strong portfolio of core blockbuster products, the “industry-leading” productivity of its innovation model, and the pending acquisition of Swiss-based biotech company Actelion.
“With a growing core business of differentiated medicines and a strong line-up of innovative products expected to launch or file over the next five years, we are leading the industry in advancing the health of patients around the world,” said Alex Gorsky, chairman and CEO. “Our pharmaceutical business will continue to be a significant driver of innovation and growth for Johnson & Johnson. With our proven global commercial capabilities and robust pipeline, we are well-positioned to continue delivering strong, long-term, sustainable growth.”